Advertisement
Home Tags Cancer: Misc.

Tag: Cancer: Misc.

For patients with cancer and COVID-19

ASCO: Mortality High for Cancer Patients With COVID-19

Factors linked to 30-day mortality include age, male sex, smoking status, comorbidities, active cancer
Despite adoption of enhanced safety measures

Radiation Oncology Clinic Visits Down Due to COVID-19

Patient volume decreased despite vast majority of practices adopting enhanced safety practices

May 2020 Briefing – Hematology & Oncology

Here are what the editors at HealthDay consider to be the most important developments in Hematology & Oncology for May 2020. This roundup includes...
Modest delays in cancer surgery due to the COVID-19 pandemic could have a significant impact on survival

Delays in Cancer Surgery Due to COVID-19 Could Harm Survival

Per-patient delay of three or six months would result in an estimated 92,214 or 208,275 life-years lost
Among pediatric cancer patients

11.2 Percent of Pediatric Cancer Patients Positive for SARS-CoV-2

Rate of positivity 29.3 percent among screen- or symptom-positive patients; 2.5 percent in asymptomatic patients
Opioid-related deaths in the cancer population are much rarer than in the general population

Opioid-Related Deaths Less Likely Among Cancer Patients

Mortality lower despite common opioid prescriptions for cancer-related pain
Nearly half of cancer research has been stopped due to the COVID-19 pandemic

COVID-19 Pandemic Slowing Cancer Research

Findings based on survey of American Cancer Society research grantees
For pediatric and adolescent and young adult patients with specific cancers

PM2.5 Linked to Later Mortality in Certain Pediatric, AYA Cancers

Mortality risk increased at 5 years, 10 years among those with pediatric lymphomas, CNS tumors
Inflammatory bowel disease patients do not have a higher risk for female genital tract malignancies

IBD Not Tied to Female Genital Tract Malignancies

Findings seen in a national sample of Dutch patients from 1991 to 2015
For patients with low-grade upper tract urothelial cancer

UGN-101 Active in Chemoablation of Upper Tract Urothelial Cancer

Fifty-nine percent of patients had complete response at four to six weeks after initial therapy